Domestic formulations: IPM growth for 4QFY14 (Jan 14 + Feb 14) is at 6.6% YoY, Companies that have witnessed higher than industry growth in 2M are Sun Pharma (+17.8%), Torrent (+15.7%), Zydus Cadila (+5.9%), Ipca (+26.6%), DRL (+4.5%), Cipla (+5.5%), Lupin (+12.4%), and Alembic Pharma (+12.1%). US market: Overall, there were 21 ANDA approvals in the US market. Lupin has got maximum 5 approvals in our space, Zydus Cadila has 4 approvals while DRL and Sun Pharma has got 3 approvals each. In midcaps, Ipca Labs has received 2 approvals while Alembic and Unichem have also got 1 approval each
READ MORE »Posts tagged Karvy
Karvy’s Model Portfolio Of Best Mid-Cap Stocks Using Quant Strategy
Top 15 Picks based on Low P/BV, Low P/E, ROE, ROA. These are the Stocks selected based on aggregated Z‐value. Which has potential to give good return in next 6‐9 months in the BSE‐Midcap Space
READ MORE »Punjab National Bank: Karvy Research Report
In case of Punjab National Bank (PNB), as on end-March’ 10, Punjab National Bank (PNB)‘s total gross NPAs was Rs32.1 bn (1.71% of gross advances) and increased to Rs36.1 bn (1.82% of gross advances). Out of total exposure, Rs3.0 bn has been recognized as NPAs and provided for in Q1FY11 but extent of provisioning is unknown. In a worst case scenario, if Punjab National Bank (PNB) writes-off entire exposure in FY11, EPS would decline by close to 6.5% to Rs 131 and book value would drift by close to 1.4% to Rs613. We await complete clarity on the issue to effect the change in earning estimates and target price. We maintain our earning estimates and Out Performer rating with a target price of Rs1,562 at 2.2x adjusted book value FY12
READ MORE »